{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T07:31:23.857737+00:00","company":{"ticker":"NUVB","cik":1811063,"company_name":"Nuvation Bio Inc."},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"45e5105f4a4961b5b7afe3ae9270a9cf5e776197","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$18.5 million"},"claim":"Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.","evidence_excerpt":"Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-204056","anchor_url":"https://secwatch.observer/filing/0001193125-26-204056#claim-45e5105f4a4961b5b7afe3ae9270a9cf5e776197","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm"},{"fact_type":"material_agreement","fact_key":"35d41ded5d1c9250837e68641e0b28269023cbac","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2026-01-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Eisai Co., Ltd.","effective_date":"2026-01-11","item_codes_triggered":["1.01"],"value_text":"€50 million"},"claim":"Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).","evidence_excerpt":"On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-009826","anchor_url":"https://secwatch.observer/filing/0001193125-26-009826#claim-35d41ded5d1c9250837e68641e0b28269023cbac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm"},{"fact_type":"executive_change","fact_key":"40fc524739","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2025-02-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-11","interim":false,"role":"Member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..","evidence_excerpt":"Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-025099","anchor_url":"https://secwatch.observer/filing/0001193125-25-025099#claim-40fc524739","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm"},{"fact_type":"executive_change","fact_key":"0ae9afbc25","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2025-02-12T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-12","interim":false,"role":"Chief Executive Officer of AnHeart Therapeutics","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..","evidence_excerpt":"On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-025099","anchor_url":"https://secwatch.observer/filing/0001193125-25-025099#claim-0ae9afbc25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm"},{"fact_type":"executive_change","fact_key":"e367d1d364","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2024-10-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-07","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Philippe Sauvage was appointed as Chief Financial Officer at Nuvation Bio Inc..","evidence_excerpt":"Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-233794","anchor_url":"https://secwatch.observer/filing/0001193125-24-233794#claim-e367d1d364","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524233794/0001193125-24-233794-index.htm"},{"fact_type":"earnings_release","fact_key":"1f95aaa2abb54902c2770c17d82965afd608f6f8","cik":1811063,"ticker":"NUVB","company_name":"Nuvation Bio Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$(0.07) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$14.8 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.","evidence_excerpt":"For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-138263","anchor_url":"https://secwatch.observer/filing/0001193125-24-138263#claim-1f95aaa2abb54902c2770c17d82965afd608f6f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm"}]}